A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Summary

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).

Timeline

Start

2026-05-23

Primary completion

2028-08-11

Completion

2030-10-30

Drugs

Indications